aThis was not a randomized trial and the monotherapy and combination therapy arms were not comparator arms. CONSORT indicates Consolidated Standards of Reporting Trials.
Tumor-infiltrating CD8+ T cells (P = .72) (A) and FoxP3+ regulatory T cells (P = .44) (B) by immunohistochemistry biopsies before treatment and while receiving treatment for 53 matched pairs of patients receiving BMS-986156 plus nivolumab combination therapy (all patients included in this analysis received 240 mg of nivolumab every 2 weeks). The Wilcoxon signed rank test was performed for all the comparisons. The horizontal line in each box plot denotes the median level. C1 D15 indicates cycle 1, day 15.
eFigure 1. Study Design Schematic of NCT02598960
eFigure 2. Pharmacokinetics of BMS-986156 and BMS-986156 Plus Nivolumab
eFigure 3. Peripheral CD8 T-Cell and Natural Killer (NK)-Cell Proliferation in Response to BMS-986156 Monotherapy and BMS-986156, Alone and In Combination With Nivolumab Therapy
eFigure 4. Peripheral Regulatory T-cell (Treg) Depletion After BMS-986156 Plus Nivolumab Therapy
eTable 1. Patient Demographics and Baseline Characteristics in the Monotherapy and Combination Cohorts
eTable 2A. Treatment Exposure: BMS-986156 Monotherapy
eTable 2B. Treatment Exposure: BMS-986156 Plus Nivolumab Combination Therapy
eTable 3A. TRAEs in the BMS-986156 Monotherapy Dose Cohorts
eTable 3B. TRAEs in the BMS-986156 Plus Nivolumab Dose Cohorts
eTable 4. Serious TRAEs in the BMS-986156 Monotherapy and BMS-986156 Plus Nivolumab Cohorts
eTable 5. Causes of Death
eTable 6A. Immunogenicity in the BMS-986156 Monotherapy Cohort by Dose
eTable 6B. Immunogenicity in the BMS-986156 Plus Nivolumab Cohorts by Dose
eTable 7. Efficacy — ORR and DCR Per Investigator in the BMS-986156 Plus Nivolumab Combination Cohort by Tumor Type
Data Sharing Statement
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Heinhuis KM, Carlino M, Joerger M, et al. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. JAMA Oncol. Published online November 07, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.3848
Is the glucocorticoid-induced tumor necrosis factor receptor–related protein agonist BMS-986156 treatment with or without nivolumab tolerable and clinically active in patients with advanced solid tumors?
In this open-label, phase 1/2a study of 292 treated patients with advanced solid tumors (69 completed initial treatment), BMS-986156 therapy had a tolerable safety profile; combination therapy had a similar safety profile to that of nivolumab. No responses were seen with monotherapy; however, in combination therapy, response rates were comparable to those historically observed with nivolumab (<15% across tumor types).
This study represents the largest data set on glucocorticoid-induced tumor necrosis factor receptor–related protein agonism with or without nivolumab to our knowledge; a clear signal has not emerged demonstrating that glucocorticoid-induced tumor necrosis factor receptor–related protein agonism may be an effective therapeutic strategy in a broad patient population.
Multiple immunostimulatory agonist antibodies have been clinically tested in solid tumors to evaluate the role of targeting glucocorticoid-induced tumor necrosis factor (TNF) receptor–related protein in anticancer treatments.
To evaluate the safety and activity of the fully human glucocorticoid-induced TNF receptor–related protein agonist IgG1 monoclonal antibody BMS-986156 with or without nivolumab in patients with advanced solid tumors.
Design, Setting, and Participants
This global, open-label, phase 1/2a study of BMS-986156 with or without nivolumab enrolled 292 patients 18 years or older with advanced solid tumors and an Eastern Cooperative Oncology Group performance status of 1 or less. Prior checkpoint inhibitor therapy was allowed. Monotherapy and combination dose-escalation cohorts ran concurrently to guide expansion doses beginning October 16, 2015; the study is ongoing.
The protein agonist BMS-986156 was administered intravenously at a dose of 10, 30, 100, 240, or 800 mg every 2 weeks as monotherapy, and in the combination group 30, 100, 240, or 800 mg plus 240 mg of nivolumab every 2 weeks; same-dose cohorts were pooled for analysis. One cohort also received 480 mg of BMS-986156 plus 480 mg of nivolumab every 4 weeks.
Main Outcomes and Measures
The primary end points were safety, tolerability, and dose-limiting toxic effects. Additional end points included antitumor activity per Response Evaluation Criteria in Solid Tumors, version 1.1, and exploratory biomarker analyses.
With a follow-up range of 1.4 to 101.7 weeks (follow-up ongoing), 34 patients (16 women and 18 men; median age, 56.6 years [range, 28-75 years]) received monotherapy (4 patients completed initial treatment), and 258 patients (140 women and 118 men; median age, 60 years [range, 21-87 years]) received combination therapy (65 patients completed initial treatment). No grade 3 to 5 treatment-related adverse events occurred with BMS-986156 monotherapy; grade 3 to 4 treatment-related adverse events occurred in 24 patients (9.3%) receiving BMS-986156 plus nivolumab, with no grade 5 treatment-related adverse events. One dose-limiting toxic effect (grade 4 elevated creatine phosphokinase levels) occurred in a patient receiving 800 mg of BMS-986156 plus 240 mg of nivolumab every 2 weeks; BMS-986156 with or without nivolumab exhibited linear pharmacokinetics with dose-related increase after a single dose. Peripheral T-cell and natural killer–cell proliferation increased after administration of BMS-986156 with or without nivolumab. No consistent and significant modulation of intratumoral CD8+ T cells and FoxP3+ regulatory T cells was observed. No responses were seen with BMS-986156 alone; objective response rates ranged from 0% to 11.1% (1 of 9) across combination therapy cohorts, with a few responses observed in patients previously treated with anti–programmed death receptor (ligand) 1 therapy.
Conclusions and Relevance
Based on this cohort, BMS-986156 appears to have had a manageable safety profile, and BMS-986156 plus nivolumab demonstrated safety and efficacy comparable to historical data reported for nivolumab monotherapy.
ClinicalTrials.gov identifier: NCT02598960
Immunotherapy treatment options are broad and include multiple approaches. One of the most successful strategies thus far has been the blockade of T-cell inhibitory checkpoints, such as cytotoxic T-lymphocyte–associated antigen 4 and programmed death receptor 1 (PD-1), and programmed death ligand 1 (PD-L1), to enhance the antitumor immune response.1 Immune checkpoint inhibitors lead to highly durable responses and significantly prolonged overall survival in many advanced tumor types.2-4 Dual checkpoint blockade, combining nivolumab with ipilimumab, has shown even more promising results in various tumor types.5-10 Although checkpoint inhibitors have provided advancements in anticancer treatment, a significant majority of patients, such as those with tumor types that are mismatch repair proficient or noninflamed, remain unresponsive to checkpoint inhibition.11-14 In addition, some patients with initial response to checkpoint inhibition eventually experience disease progression and face limited subsequent therapeutic options. Thus, new strategies for modulating the critical balance of T-cell activation and antigen tolerance that make an antitumor immune response possible are being investigated.15-18
A variety of T-cell costimulatory receptors exist whose activity and engagement may potentiate the T-cell response induced by checkpoint inhibitors. Promising therapeutic targets include the tumor necrosis factor receptor (TNFR) superfamily, such as the glucocorticoid-induced TNFR-related protein (GITR), TNFR superfamily member 4 (CD134/OX40), and TNFR superfamily member 9 (CD137/4-1BB). It was hypothesized that agonistic GITR antibodies may successfully activate costimulatory pathways to synergize with PD-1 inhibitors and PD-L1 inhibitors in the tumor microenvironment.1 To date, several anti-GITR antibodies and anti-GITR ligand antibodies have been used in clinical trials.19-26
The protein agonist BMS-986156 is an IgG1 agonist monoclonal antibody to GITR, a molecule that is constitutively expressed by intratumoral regulatory T cells at high levels and by effector T cells at low levels.27 In addition, GITR becomes upregulated on effector T cells on their activation. In preclinical studies, GITR engagement can deplete GITR-expressing cells or can induce T-cell proliferation depending on the system.27,28 BMS-986156 was engineered to increase T-cell activation and deplete intratumoral regulatory T cells in combination with anti–PD-1 therapy. Preclinical experiments with in vivo syngeneic mouse models show enhanced antitumor activity when a GITR agonist antibody is added to anti–PD-1 therapy.29 Thus, it was hypothesized that this combination may result in improved and prolonged antitumor responses in patients with advanced cancer.
In the present study, results are reported from a phase 1/2a dose-escalation and dose-expansion study investigating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity profiles of BMS-986156 as monotherapy treatment and in combination with nivolumab in patients with advanced solid tumors (NCT02598960).30
Twenty-seven sites across Australia, Belgium, Canada, France, Germany, Italy, the Netherlands, Spain, Switzerland, and the United States participated in this study, which began October 16, 2015, and is ongoing. Eligible patients were aged 18 years or older with confirmed, previously treated advanced solid tumors per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.131 and must have received and then progressed on or been intolerant to 1 or more standard treatment regimens in the advanced or metastatic setting, if such a therapy existed. Other key eligibility criteria included an Eastern Cooperative Oncology Group performance status of 1 or less. Prior anti–PD-1 therapy or anti–PD-L1 therapy was allowed. The study was conducted in compliance with the trial protocol (Supplement 1). The protocol, any amendments, and the patient informed consent form were reviewed and approved by an institutional review board or independent ethics committee (Australia: Linear Clinical Research Ltd, Liverpool Cancer Therapy Center, Princess Alexandra Hospital, Westmead Hospital; Belgium: Universitair Ziekenhuis Gent; Canada: Cross Cancer Institute, Princess Margaret Cancer Centre; France: Centre Claudius Regaud, Institut Curie, Institut Gustave Roussy; Germany: Klinikum Der Albrecht-Ludwigs-Universitat, Med. Klinik Und Poliklinik D. Uni Wuerzburg, Universitaetsklinikum Bonn; Italy: Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori Milano, Istituto Europeo Di Oncologia; Netherlands: NKI AVL; Spain: Fundacion Jimenez Diaz, Hosp Univer 12 De Octubre; Switzerland: Cantonal Hospital St Gallen, University Hospital Zurich; United States: Emory University, Providence Portland Medical Center, The Ohio State University, The West Clinic P.C., Thomas Jefferson University Hospital, University of California San Diego Moores Cancer Center, University of Alabama at Birmingham) prior to initiation of the study. Patients provided written informed consent.
This phase 1/2a, open-label study investigated BMS-986156 as monotherapy and in combination with nivolumab (study design, doses, and Consolidated Standards of Reporting Trials [CONSORT] diagram shown in Figure 1; trial protocol in Supplement 1; and eFigure 1 in Supplement 2).
The primary objective of this study was to determine the safety, tolerability, dose-limiting toxic effects, and maximum tolerated dose of BMS-986156 either as monotherapy or in combination with nivolumab in patients with advanced solid tumors. Key secondary objectives included determining the antitumor activity and characterizing the pharmacokinetic profile and immunogenicity of BMS-986156 as monotherapy and in combination with nivolumab. Exploratory end points included nivolumab pharmacokinetics, overall survival, and the pharmacodynamics of BMS-986156 plus nivolumab via peripheral blood and intratumoral biomarker analysis.
Adverse events were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.32 Adverse events were evaluated throughout the study while participants were receiving treatment and until 100 days after study completion.
Assessment of tumor response was observed through computed tomography and/or magnetic resonance imaging at the start of the study and every 8 weeks until disease progression or treatment termination via RECIST, version 1.1.
Detailed information on exclusion criteria, study treatment, and statistical, pharmacokinetic, and pharmacodynamic analyses are described in the eAppendix in Supplement 2.
Detailed patient demographics are presented in eTable 1 in Supplement 2. Baseline characteristics were similar between the monotherapy and combination therapy cohorts. Prior anti–PD-1 or anti–PD-L1 therapy was received by 11 of 34 patients (32.4%) in the monotherapy cohort and 51 of 258 patients (19.8%) in the combination cohort.
As of March 27, 2018, 34 patients received 10 to 800 mg of BMS-986156 monotherapy every 2 weeks and 258 patients received 30 to 800 mg of BMS-986156 plus 240 mg of nivolumab every 2 weeks or 480 mg of BMS-986156 plus 480 mg of nivolumab every 4 weeks. Duration of therapy ranged from 2.0 to 61.0 weeks, with follow-up time ranging from 1.4 to 101.7 weeks. Median treatment exposure (in weeks) is presented in eTables 2A and 2B in Supplement 2. All patients but 1 (n = 33) were able to receive 90% or more of the planned cumulative treatment dose of BMS-986156 in the dose-escalation phase (4 patients completed initial treatment), and more than 80% of patients in each dose cohort of the combination phase (n = 227) were able to receive 90% or more of the planned cumulative treatment dose of both drugs (65 patients completed initial treatment).
Overall, the safety profile of BMS-986156 was tolerable. Any treatment-related adverse events (TRAEs) by dose in the BMS-986156 monotherapy cohort and in 5% or more of patients in the BMS-986156 plus nivolumab combination cohorts, as well as any grade 3 or 4 TRAEs in either cohort, are shown in eTables 3A and 3B in Supplement 2. Grades 3 and 4 TRAEs occurred in 24 patients (9.3%) receiving BMS-986156 plus nivolumab. No grade 5 TRAEs were observed with either treatment. In addition, no TRAEs led to treatment discontinuation in the BMS-986156 monotherapy cohort. Three TRAEs led to treatment discontinuation of BMS-986156 plus nivolumab (grade 3 colitis, infusion-related reaction, and pancreatitis, all in the cohort receiving 240 mg of BMS-986156 plus 240 mg of nivolumab). Grade 1 to 2 pyrexia was seen in 6 patients (17.6%) treated with BMS-986156 monotherapy and 28 patients (10.9%) treated with combination therapy, usually within 24 hours of infusion without associated sequelae. Any grade and grades 3 and 4 serious TRAEs occurring in the overall monotherapy and combination cohorts are shown in eTable 4 in Supplement 2. Grade 2 pneumonitis was the only serious TRAE seen in patients treated with BMS-986156 monotherapy. With combination therapy, most serious TRAEs were observed in the 202 patients who received 240 mg of BMS-986156 plus 240 mg of nivolumab every 2 weeks. One dose-limiting toxic effect (grade 4 elevated creatine phosphokinase level) occurred in a patient receiving 800 mg of BMS-986156 plus 240 mg of nivolumab every 2 weeks. Causes of death in the trial are shown in eTable 5 in Supplement 2.
The pharmacokinetics for BMS-986156 monotherapy and BMS-986156 plus nivolumab combination after the first dose is shown in eFigure 2 in Supplement 2. Overall, the pharmacokinetics was linear and exhibited a dose-related increase in exposure that was not affected in combination with nivolumab.
Immunogenicity with BMS-986156 monotherapy was low; only 1 of 31 patients (at the dose of 10 mg every 2 weeks) was antidrug antibody (ADA) positive, and no patients had persistent ADA positivity (eTable 6A in Supplement 2). In the combination cohort, the frequency of anti-GITR antibodies at all tested doses of BMS-986156 remained low, with 223 of 229 patients (97.4%) remaining ADA negative, and no persistently ADA-positive patients. Immunogenicity with nivolumab was relatively higher, with 35 of 223 ADA-positive patients (15.7%), and 1 of 223 patients (0.4%) persistently positive, which is consistent with nivolumab monotherapy (eTable 6B in Supplement 2).
In analyzed patients, there was a trend toward an increase in CD8+ T-cell and natural killer–cell proliferation after administration of anti-GITR monotherapy tested up to a dose of 240 mg every 2 weeks, although patient numbers were small (eFigure 3 in Supplement 2). Enhanced CD8+ T-cell and natural killer–cell proliferation was observed in the combination cohort.
In the subset of patients with data available at baseline and all analyzed time points, results of flow cytometry revealed no clear depletion of regulatory T cells in the peripheral blood in response to BMS-986156 plus nivolumab (eFigure 4 in Supplement 2). In addition, CD8+ T cells and FoxP3+ regulatory T cells as assessed by immunohistochemistry revealed interpatient variability from before treatment to the treatment period with BMS-986156 plus nivolumab (Figure 2).
Response results for the BMS-986156 monotherapy cohort and the BMS-986156 plus nivolumab combination cohort are summarized in Table 1 and Table 2, and response results by tumor type for the combination treatment cohort are summarized in eTable 7 in Supplement 2. No complete or partial responses were observed with BMS-986156 alone. Objective response rates ranged from 0% to 11.1% (1 of 9) across combination therapy cohorts; an objective response rate of 9.0% (18 of 200) was observed in the patient cohort evaluable for response who received 240 mg of BMS-986156 plus 240 mg of nivolumab.
Here, results are presented from a phase 1/2a dose-escalation and dose-expansion study of the GITR agonistic antibody BMS-986156 with or without nivolumab in 292 patients with advanced solid tumors. Overall, the safety profile of BMS-986156 monotherapy appeared to be manageable, with no unanticipated safety signals, no dose-limiting toxic effects, and no treatment discontinuations owing to TRAEs. The findings suggest that the safety profile of BMS-986156 plus nivolumab at all doses was manageable and tolerable and was similar to that of nivolumab alone.2,33,34 The rate of infusion-related reactions with combination therapy was the only TRAE that potentially appeared more frequently than observed with nivolumab alone.2,33,34
Some limitations of this trial include the absence of comparator groups and the enrollment of an unselected population. For example, although combination therapy with BMS-986156 plus nivolumab yielded pharmacodynamic changes and clinical response rates similar to those historically observed with nivolumab monotherapy in patients with advanced solid tumors (range, 13%-20%),2,33-35 this trial was not designed to be a head-to-head comparison of nivolumab monotherapy vs nivolumab plus BMS-986156. Thus, without an appropriate comparator group (eg, nivolumab monotherapy), dissecting the effects of BMS-986156 and nivolumab is difficult, and the contribution of the GITR agonist to the combinatorial clinical activity remains unclear. In addition, no tumor type appeared to respond more favorably to combination therapy vs others. Most observed responses occurred in patients without prior anti–PD-1 or anti–PD-L1 therapy, although a few responses were observed in patients with prior anti–PD-1 or anti–PD-L1 therapy. Overall, however, the data appear to indicate the absence of substantial clinical activity of BMS-986156 in an unselected, broad population of patients with advanced solid tumors.
Similar observations of a tolerable safety profile and some immunomodulatory action, but limited clinical activity, have been made with other GITR agonist antibodies in clinical trials; across 4 other studies, more than 100 patients have been treated with GITR agonist monotherapy, demonstrating a manageable safety profile and limited clinical activity (the best overall response observed was stable disease).19,21,22,36 Based on current available data, to date, no synergistic activity has been observed between GITR agonists and pembrolizumab when administered as a combination treatment, except potentially in checkpoint inhibitor–naive patients with melanoma, based on a small cohort of 13 patients.21,37
Although checkpoint inhibitors have made strides in revolutionizing cancer therapy, to our knowledge, there has not been a clear path identified to date for costimulatory therapy combinations. Other members of the TNFR superfamily and classes of costimulatory molecules that are mechanistically different from TNFR are also under investigation, including inducible costimulator, a member of the CD28 family, which promotes T-cell proliferation and cytokine production after T-cell activation.15 The potential role of combination checkpoint inhibition plus agonistic induction of costimulatory T-cell pathways in certain patient subsets with immunotherapy-resistant or refractory tumors remains to be determined.
To our knowledge, this represents the largest clinical data set investigating GITR agonist therapy (BMS-986156) with or without nivolumab. We believe that BMS-986156 has a manageable safety profile, and its combination with nivolumab seems to show a similar safety signal to that of nivolumab monotherapy. Clinical activity of anti-GITR therapy plus anti–PD-1 therapy was similar to historically observed activity with anti–PD-1 therapy alone. Thus, no evidence of monotherapeutic clinical activity for GITR agonism was observed in this broad population. In addition, no clear signal has emerged to date demonstrating that GITR agonism may be an effective therapeutic strategy in a broad patient population.
Accepted for Publication: July 7, 2019.
Published Online: November 7, 2019. doi:10.1001/jamaoncol.2019.3848
Open Access: This article is published under the JN-OA license and is free to read on the day of publication.
Corresponding Author: Lillian L. Siu, MD, FRCPC, Bras and Family Drug Development Program, Princess Margaret Cancer Centre, 700 University Ave, Hydro Building, Seventh Floor, Room 7-624, Toronto, Ontario M5G 1Z5, Canada (email@example.com).
Author Contributions: Drs Patah and Siu had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Heinhuis and Carlino are co–first authors.
Concept and design: Heinhuis, Paz-Ares, Curigliano, Patah, Liu, Bajaj, Siu.
Acquisition, analysis, or interpretation of data: Heinhuis, Carlino, Joerger, Di Nicola, Meniawy, Rottey, Moreno, Gazzah, Delord, Britschgi, Schilder, O’Byrne, Curigliano, Romano, Patah, Wang, Liu, Bajaj, Siu.
Drafting of the manuscript: Heinhuis, Carlino, Joerger, Di Nicola, Paz-Ares, O’Byrne, Curigliano, Patah, Liu, Bajaj, Siu.
Critical revision of the manuscript for important intellectual content: Heinhuis, Carlino, Joerger, Meniawy, Rottey, Moreno, Gazzah, Delord, Paz-Ares, Britschgi, Schilder, O’Byrne, Curigliano, Romano, Patah, Wang, Bajaj, Siu.
Statistical analysis: Paz-Ares, Curigliano, Wang, Liu.
Administrative, technical, or material support: Carlino, Joerger, Delord, Schilder, Romano, Patah, Wang, Bajaj, Siu.
Supervision: Carlino, Joerger, Di Nicola, Rottey, Moreno, Gazzah, Paz-Ares, Curigliano, Patah, Wang, Siu.
Conflict of Interest Disclosures: Dr Carlino reported receiving personal fees for serving as an advisory board member and receiving honoraria from Bristol-Myers Squibb and Merck Sharp & Dohme and for serving as an advisory board member for Novartis, and Pierre Fabre outside the submitted work. Dr Meniawy reported receiving research funding for this sponsored study from Bristol-Myers Squibb; and serving on the advisory board for Bristol-Myers Squibb Australia. Dr Rottey reported receiving honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and Roche; serving in a consulting or advisory role (institutional) for Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and Roche; receiving research funding (institutional) from Roche; and receiving travel and accommodations expenses from Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and Roche. Dr Moreno reported receiving consulting fees from Merck; receiving travel support from Regeneron/Sanofi; delivering presentations to Nanobiotix; and receiving an educational grant from Medscape/Bayer. Dr Gazzah reported receiving travel, accommodation, and congress registration expenses from Boehringer Ingelheim, Novartis, Pfizer, and Roche; serving as a consultant or in an expert role for Novartis; and receiving research funding from AbbVie, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Daiichi Sankyo, Debiopharm SA, Eisai, Eli Lilly, Exelixis, Forma, Gamamabs, Genentech Inc, GlaxoSmithKline, H3 Biomedicine Inc, Hoffmann La Roche Ag, Innate Pharma, Iris Servier, Janssen Cilag, Kyowa Kirin Pharm Dev Inc, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Roche, Sanofi Aventis, Taiho Pharma, Tesaro Inc, and Xencor. Dr Delord reported serving in a consulting or advisory role for Novartis, Roche/Genentech, Bristol-Myers Squibb, and MSD Oncology; and receiving research funding (institutional) from Genentech, Bristol-Myers Squibb, MSD Oncology, and AstraZeneca. Dr Paz-Ares reported receiving personal fees for serving as a medical advisor for Roche, Lilly, Novartis, AstraZeneca, Boehringer Ingelheim, MSD, Bristol-Myers Squibb, Amgen, Pharmamar, Takeda, Pfizer, Merck, Celgene, and Sanofi outside the submitted work. Dr Britschgi reported receiving personal fees for serving as a consultant for Roche, AstraZeneca, Takeda, Boehringer Ingelheim, and Pfizer outside the submitted work. Dr Schilder reported receiving a grant from Bristol-Myers Squibb; and personal fees from Incyte, Immunogen, Celsion, and FlatIron outside the submitted work. Dr O’Byrne reported having stock and other ownership interests in CARP Pharmaceuticals; receiving honoraria from Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, Teva, Boehringer Ingelheim, AstraZeneca, Pfizer/EMD Serono, Novartis, Janssen-Cilag, and Mundipharma; serving in a consulting or advisory role for Merck Sharp & Dohme, Boehringer Ingelheim, Roche/Genentech, Janssen-Cilag, Pfizer, AstraZeneca/MedImmune, Bristol-Myers Squibb, Novartis, Teva, and Natera; serving on the speakers’ bureau for Merck Sharp & Dohme, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, Janssen-Cilag, Pfizer, Mundipharma, Novartis, and Foundation Medicine; receiving research funding from AstraZeneca/MedImmune, and Bristol-Myers Squibb; holding 4 patents held by University of Queensland; and receiving travel and accommodations expenses from Boehringer Ingelheim, Bristol-Myers Squibb, and Roche. Dr Curigliano reported being an expert advisory board member for Bristol-Myers Squibb, Roche, Novartis, Lilly, Pfizer, Seattle Genetics, and Samsung; and serving on the scientific advisory board for Ellipsis. Dr Romano reported receiving research funding from Bristol-Myers Squibb; and serving as a consultant for Roche. Dr Patah reported being an employee of Bristol-Myers Squibb. Dr Wang reported being an employee of Bristol-Myers Squibb. Dr Liu reported being an employee of Bristol-Myers Squibb. Dr Bajaj reported being an employee of Bristol-Myers Squibb. Dr Siu reported serving as a consultant for Merck, Pfizer, Celgene, AstraZeneca/MedImmune, Morphosys, Roche, GeneSeeq, Loxo, Oncorus, and Symphogen; and receiving clinical trial support (institution) from Novartis, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Regeneron, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca/MedImmune, Merck, Celgene, Astellas, Bayer, AbbVie, Amgen, Symphogen, Intensity Therapeutics, Mirati, and Agios.
Funding/Support: This study was sponsored and funded by Bristol-Myers Squibb.
Role of the Funder/Sponsor: Bristol-Myers Squibb was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 3.
Additional Contributions: Neeltje Steeghs, MD, PhD, Netherlands Cancer Institute, provided guidance and oversight of the initial design and concept of the NCT02598960 study. Medical writing support was provided by Ina Nikolaeva, PhD, Healthcare Consultancy Group, and was funded by Bristol-Myers Squibb Company. We also thank the patients and families who made this study possible and the clinical study teams who participated in the study.
Create a personal account or sign in to: